Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Verisante Technology Inc. V.VRS


Primary Symbol: V.VER.H

Verisante Technology Inc is a Canada based medical device company. It is engaged in commercializing medical systems for the early detection of cancer. The products of the company are Verisante Aura which is for skin cancer detection and Verisante Core which is for lung, colon and cervical cancer detection. It utilizes a cancer detection platform while the operating software and probe technology. The group generates revenue from the sale and renting of its medical devices.


TSXV:VER.H - Post by User

Bullboard Posts
Post by herbaciouson Mar 23, 2011 8:51pm
315 Views
Post# 18331567

WANNA KNOW WHY ?is the time to BUY

WANNA KNOW WHY ?is the time to BUYvery simple:

Lets talk AURA:

Verisante's AURA DEVICE was developed jointly by the BC Cancer Agency and the University of British Columbia Faculty of Medicine.

AURA was developed by a team of award winning physicians nd engineers with decades of combned experience in the fiel of cancer imaging.

VERISANE has an EXCLUSIVE LICENCE to the technology, which includes THE rights to develop , commercialize and sell follow-on devices   for detection  of other  types of cancer.

Terms of the  license include  Verisante paying  the BCCancer  Agency   6% royalty on sales.

ABOUT AURA

AURA scans for 21 different cancer biomarkers in less  than one second.

in then compares the signature of the scanned mole to a database to determine whether it should be biopsied.
in contrast to the traditional method of waiting for biopsy results which can take weeks, the AURA provides immediate results.

the device has been developed to be simple to operate, allowing use by trained technicians and physician assistants.

this not only frees up physicians to treat more patients , it also reduces the examination costs.
AURA can scan numerous moles within minutes and, unlike traditional ABCD method , makes full-body scans practical.

The device was used in a six year study on over 1.000 lesions.Results were confirmed with a biopsy.
Preliminary results 0n 274 lesions showed AURA correctly identified 100% of all malignant melanomas (and 90% of all cancerous and precancerous lesions) with only 30% falses positives (25% false positives of all cancerous and precancerous lesions)  In January 2011 Verisante  entered an agreement with the SKIN CARE CENTRE OF VANCOUVER GENERAL HOSPITAL DEPARTMENT  OF DERMATOLOGY AND SKIN SCIENCE, UBC for the statistical analysis of this study.

RESULTS OF THE ANALYSIS ARE EXPECTED MAY 2011.

Tomorrow
 i will report
VERISANTE'S expected launch of CORE FOR THE DETECTION OF LUNG CANCER!


Be smart, timing is everything, the opportunity is being handed to you!

do your own due diligence

herb
Bullboard Posts